insights_auto
Bakit bumaba ang EVO 2.42%?
Tingnan ang Higit pang Detalyechevron_right
EVO:NASDAQ
Evotec SE
$1.53
arrow_downward
-2.42%(-0.038) 1D
Okt 9, 12:09:06 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa EVO...
Buksan
$1.56
Mataas
$1.57
Mababa
$1.53
Mkt. cap
546.03M
Avg. na dami
144.93K
Dami
14.69K
Mataas nang 52-wk
$4.27
Mababa nang 52-wk
$1.50
EPS
-$0.62
Beta
1.98
Mga natitirang share
355.82M
Bilang ng mga empleyado
4K
Buksan
$1.56
Mataas
$1.57
Mababa
$1.53
Mkt. cap
546.03M
Avg. na dami
144.93K
Dami
14.69K
Mataas nang 52-wk
$4.27
Mababa nang 52-wk
$1.50
EPS
-$0.62
Beta
1.98
Mga natitirang share
355.82M
Bilang ng mga empleyado
4K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
AD HOC NEWS
·
9 oras ang nakalipas
Evotec stock loses 0.35 percent pre-market to EUR 2.82
AD HOC NEWS
·
23 oras ang nakalipas
Evotec stock loses 3.44 percent after-hours to EUR 2.81
AD HOC NEWS
·
1 araw ang nakalipas
Berenberg keeps Hold for Evotec stock at EUR 3.60 target
AD HOC NEWS
·
3 araw ang nakalipas
Evotec loses research chief and Evotec stock gains 2.36 percent
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Tungkol sa Evotec SE